Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 9, 2000, Pages 13-19

  Pegram, M ^a   Slamon, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN; MEMBRANE PROTEIN HER2; MEMBRANE PROTEIN NEU; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; BREAST CARCINOMA; CELL PROLIFERATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HUMAN; RECEPTOR, ERBB-2;

EID: 0033779252     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues
3. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer
4. Requirement for neuroregulin receptor erbB2 in neural and cardiac development
5. Multiple essential functions of neuregulin in development
6. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling
7. Coexpression of erB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
8. Ligand-specific activation of HER4/p180erB4, a fourth member of the epidermal growth factor receptor family
9. HER-2/neu signal transduction in human breast and ovarian cancer
10. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
11. Identification of heregulin, a specific activator of p185erbB2
12. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells
13. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3
14. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
15. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
16. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: Implications for mammary tumors
17. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells
18. ARIA a protein that stimulates acetylcholine receptor synthesis, also induces tyrosine phosphorylation of a 185-kDa muscle transmembrane protein
19. ARIA a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family
20. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system
21. Glial growth factor rescues Schwann cells of mechanoreceptors from denervation-induced apoptosis
22. Effect of neu differentiation factor isoforms on neonatal oligodendrocyte function
23. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
24. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer
25. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
26. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
27. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor
28. Humanization of an anti-p185HER2 antibody for human cancer therapy
29. Stability of HER-2/neu expression over time and at multiple metastatic sites
30. Neuprotein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
31. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
32. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
33. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer
34. Addition of Herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
35. Overall survival (OS) advantage to simultaneous chemotherapy (Crx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
36. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
37. Efficacy and safety of Herceptin (trastuzumab, humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC)
38. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
39. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
40. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor
41. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers